23. September 2024

ECTRIMS 2024: 40th anniversary with major DKF participation

The world’s largest congress for research and treatment of multiple sclerosis (MS), ECTRIMS, is celebrating its 40th anniversary. With over 8,400 participants from 103 countries, it once again provided a platform for exchanging the latest research findings and innovative treatment methods. DKF and RC2NB researchers were on site with numerous contributions, scientific presentations and poster sessions.

2024 marks a special milestone for ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis): The world's largest congress for multiple sclerosis (MS) research is celebrating its 40th anniversary. This year, leading researchers, doctors and experts gathered at the Bella Center Copenhagen in Denmark from 17 to 20 September 2024 to present their latest findings in MS research and treatment.

Researchers from the Department of Clinical Research (DKF) and the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) contributed significantly to the scientific discussion with a variety of presentations, talks and teaching courses. Some key contributions included:

• Scientific Session: Late Breaking Abstracts
  Prof. Ludwig Kappos, who is mainly responsible for the international success of MS research in Basel, chaired the closing session on recent breakthroughs in MS research and shared the latest findings with two posters.
• Scientific Session: Clinical use of blood biomarkers
  Prof. Jens Kuhle led two sessions on the use of blood biomarkers and contributed two presentations to the program.
• Educational Session: Application of imaging to understand injury in MS and related diseases
  Prof. Cristina Granziera moderated a session on imaging techniques and shared her expertise in her presentation "MS: From immunopathology to MRI".

In total, researchers from Basel were involved in 5 teaching courses, 12 talks and over 20 posters. Basel’s standing as one of the world’s leading locations for MS research was further confirmed in the closing session, where researchers from the DKF and RC2NB were repeatedly mentioned and their contributions highlighted.